Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash flows from operating activities
Net loss	$ (32,377)	$ (65,320)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	7,400	5,648
Loss on disposal of property, plant and equipment	566	185
Unrealized depreciation on equity securities and preferred stock	1,622	22,331
Noncash dividend income	(3,926)	0
Amortization of discount/premium on investments	198	320
Equity in net loss of affiliates	4,947	5,643
Stock-based compensation expense	7,894	13,188
Shares issued as payment for services	2,915	3,083
Provision for bad debts	9	840
Deferred income taxes	(638)	(2,188)
Other noncash items	(146)	193
Receivables:
Trade	1,931	3,022
Related parties	(4,994)	7,578
Notes	0	(12)
Other	859	(168)
Inventory	2,058	1,485
Prepaid expenses and other	210	143
Other assets	(526)	839
Accounts payable	(990)	2,393
Accrued compensation and benefits	924	(10,773)
Other accrued liabilities	69	4,724
Deferred revenue	(13,011)	3,050
Related party payables	161	208
Other long term liabilities	156	(21)
Net cash used in operating activities	(24,689)	(3,609)
Cash flows from investing activities
Maturities of investments	45,000	18,000
Purchases of preferred stock and warrants	(1,161)	0
Investments in affiliates	(4,579)	(2,721)
Cash paid in asset acquisition	0	(7,244)
Purchases of property, plant and equipment	(6,343)	(4,257)
Proceeds from sale of property, plant and equipment	137	102
Proceeds from repayment of notes receivable	1,500	0
Net cash provided by investing activities	34,554	3,880
Cash flows from financing activities
Acquisitions of noncontrolling interests	(913)	0
Advances from lines of credit	1,678	812
Repayments of advances from lines of credit	(2,088)	(837)
Proceeds from long term debt	126	0
Payments of long term debt	(123)	(160)
Payments of deferred consideration for acquisitions	(1,991)	0
Proceeds from stock option exercises	175	9,777
Payment of stock issuance costs	(10)	0
Net cash provided by (used in) financing activities	(3,146)	9,592
Effect of exchange rate changes on cash and cash equivalents	526	88
Net increase in cash and cash equivalents	7,245	9,951
Cash and cash equivalents
Beginning of period	62,607	135,782
End of period	69,852	145,733
Supplemental disclosure of cash flow information
Cash paid during the period for interest	70	70
Significant noncash financing and investing activities
Stock received as consideration for collaboration agreements	0	9,333
Stock issued to acquire noncontrolling interest	5,082	0
Stock issued in asset acquisition	0	4,401
Contingent consideration assumed in asset acquisition	0	3,660
Noncash dividend to shareholders	22,385	0
Purchases of equipment included in accounts payable and other accrued liabilities	1,132	839
Proceeds from stock option exercises included in other receivables	$ 0	$ 3,553